Improve my RIS file project

Scope

- Proof of concept of sharing meta-data from existing repositories
- "Meta-data" is the added value of "appraised" evidence products
- The focus is
 - not on RIS, (i.e. can be RIS, CSV, Jason (HL7 FHIR))
 - But on building a shared knowledge base.

What does this address and what does it not address?


- It is a proof of concept for and approach to:
 - Obtaining meta-data for records from existing repositories
- It does not address:
 - Comprehensive searching (retrieving all references from all databases)
 - Federated searching (searching multiple databases at the same time)
 - De-duplication, or finding references unique to each repository
- It is a starting, not final point


Worked example

• Performing/updating a review on the value of quarantine

- Search string:
 - quarantine isolation lockdown "lock down" cordon "community containment" "containment area"
- Background:
 - ORing the terms on PubMed: 2,034,420 results
 - ANDing COVID19:

3,736 results






End-result: merged RIS

PMID	C-D	E-D	P-D	C-PICO	E-used in SR	P-quality grade
1	RCT	RCT	RCT			
2	Obs	Non-RCT	Obs			
3	Modeling	Non-RCT	Obs			
4						
5						

Still to agree on:

- Which field to export
- How to code them
- RIS vs CSV
- FIHR Json

RIS/CSV/Jason availability is the base for building a RIS/CSV/json "manager" to automate querying, merging, deduplication, etc



\leftrightarrow \rightarrow C $rac{1}{2}$	🔽 🔒 h	ttps://covid-	-19.cochrane.org		··· 🖂 🕁	👱 III\ 🗉 🚳 💿 🚾 😅 🐇 🛱 🗏
6 Getting Started ✿ Most Visited	Personale	HIRU	Open access 📋 McMaster 📋 Google tools	🗎 Clinical 🌐 Citrix XenApp - Log 🖨 Mene	🕀 My Account (🔾 McMaster Universit 📋	Coronavirus Update 🖨 Best Questions to A >>>
Cochrane COVID-19 Study Register	Trusted e Informed Better he	l decisions.		quarantine isolation lockdown "lock o	down" cordon "community containment"	About Help
UPDATED	^	Select All	Order by Newest First 🗸 Results pe	r page 15 🗸	Showing 1 - 15 of 12,262	2 studies Prev 1 2 3 4 5 6 7 Next
Last Day	124		1			
Last 3 Days	575		GUALANO 2020A			
Last Week	941		Effects of Covid-19 Lockdown on	Mental Health and Sleep Disturbances	s in Italy	
Last Month	4218		ां Study Type	(i) Study Aim	(i) Study Design	(i) Intervention Assignment
Last 3 Months	11017		Observational	Other	Case Series/Case Control/Cohort	Not Applicable
From And To			References (1)			
STUDY REFERENCE TYPE	~					
STUDY CHARACTERISTICS	~		MØLLER-SØRENSEN 2020 COVID-19 Assessment with Bedsi	de Lung Ultrasound in a Population of	Intensive Care Patients Treated with Me	chanical Ventilation and ECMO
PICO data not currently available for all s	tudies		 Study Type 	 Study Aim 	(i) Study Design	(i) Intervention Assignment
POPULATION	~		Observational	Diagnostic/Prognostic	Case Series/Case Control/Cohort	Not Applicable
INTERVENTION	~		References (1)	Treatment And Management		
OUTCOME	~					
			ZHAO 2020BA Prediction of the Number of Patie () Study Type Modelling	Infected with COVID-19 Based on I③ Study AimTransmissionEpidemiology	Rolling Grey Verhulst Models (i) Study Design Other	 intervention Assignment Not Applicable
			References (1)			

	 Cochrane CovidExport.txt 	
Cochran COVID-19 Study Register	<pre>TY - JOUR AN - 7245989 OP - NCT02735707 N1 - NCT02735707 N1 - 13266293 C7 - NCT02735707 T1 - Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia A1 - MJM Bonten</pre>	About Help
UPDATED Last Day Last 3 Days Last Week Last Month Last 3 Months	PY - 2015 T2 - ClinicalTrials.gov UR - https://clinicaltrials.gov/show/NCT02735707 AB - REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for community-acquired pneumonia. The purpose of this study is to evaluate the effect of a range of interventions to improve outcome of on patients admitted to intensive care with community-acquired pneumonia. In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple treatment modalities in the event of a respiratory pandemic resulting in critical illness. KW - Pneumonia // Lung Diseases // Respiratory Tract Diseases // Respiratory Tract Infections // Anti-Bacterial Agents // Moxifloxacin // Levofloxacin // Antibiotics // Hydrocortisone // Anti-Infective Agents // Ceftriaxone // Piperacillin-tazobactam // Ceftaroline // Amoxicillin- clavulanate // Oseltamivir // COVID-19 // Influenza // Intensive care // Critical care T2 - ClinicalTrials.gov	1 2 3 4 5 6 7 Next
STUDY REFERENCE TYPE	M3 - Interventional; <u>Randomised</u> ; Parallel/Crossover; Treatment and management; Trial registry record; OTHER; Trial record DB - Cochrane COVID-19 Register ER - TY - JOUR AN - 8246901 OP - NCT02517489 N1 - NCT02517489 N1 - 13336473 C7 - NCT02517489	le i
POPULATION	<pre>TI - Community-Acquired Pneumonia : Evaluation of Corticosteroids A1 - University Hospital, Tours PY - 2015 KW - Cortisol succinate // Hydrocortisone // Hydrocortisone 17-butyrate 21-propionate // Hydrocortisone acetate // Pneumonia T2 - ClinicalTrials.gov UR - https://clinicaltrials.gov/show/NCT02517489 AB - Mortality of severe Community-Acquired Pneumonia (CAP) has not declined over time and is</pre>	ion Assignment
OUTCOME	pulmonary and systemic inflammation, accelerate clinical resolution and decrease the rate of inflammation-associated systemic complications. Two recent meta-analyses suggest a positive effect on severe CAP day 28 survival when CTx are added to standard therapy. However they are based on only four trials gathering less than 300 patients, of which only one was positive. Recently published guidelines do not recommend CTx as part of CAP treatment. Therefore a well-powered trial appears necessary to test the hypothesis that CTx – and more specifically hydrocortisone – could improve day 28 survival of critically-ill patients with severe CAP, severity being assessed either on a Pulmonary Severity Index ≥ 130 (Fine class V) or by the use of mechanical ventilation or high-FiO2 high-flow oxygen therapy.	i
	antibiotics and supportive care, including the correction of hypoxemia.	e - January 2-February 29, Selected <u>Export</u> <u>Clear</u> le
	DB - Cochrane COVID-19 Register	

Home	AA	AB	AC	AD	ents
	Study Type	Intervention assignment	Study design detail	Study aim	
Paste	Interventional	Randomised	Parallel/Crossover	Treatment and management	
8 Possibl	ticle				As
A	Observational	Not applicable	Cross-sectional	Diagnostic/Prognostic // Epiden	
1 CRS recor 2 72459 3 82469	Observational	Not applicable	Cross-sectional	Diagnostic/Prognostic // Mecha	neadir Ot Pn I succ Co
4 83143 5 84867	B Observational	Not applicable	Cross-sectional	Diagnostic/Prognostic // Mecha	
6 125866 7 130898 8 131024	Observational	Not applicable	Case report	Epidemiology // Mechanism	predn Pn cent / Co
9 131025 10 131025	¹⁴ Wodening // Observatio	Not applicable		Epidemiology // Prevention //	An ic) // ep
11 131025 12 131025 13 131025	Observational	Not applicable	Case series/Case contro	Transmission	2077 en cent // A ronav Be
14 131025 15 131025	Second Contraction Second Seco	Not applicable	Case report	Mechanism	0253 [.] Fa Nc
16 131026 17 131026 18 131026	Modelling // Observatio	Not applicable		Epidemiology // Prevention //	hms / Alរ្ al Agents ency Serv
19 131026 20 131026	Modelling	Not applicable		Epidemiology // Prevention //	oronavirı ronav 20
21 131026 22 131026 23 131027	Observational	Not applicable	Case series/Case contro	Diagnostic/Prognostic	1001 20 0529 20 ic) // 036
24 131027 25 131027	Observational	Not applicable	Case series/Case contro	Diagnostic/Prognostic // Mecha	Ad oronaviru
26 131027 27 131027 28 131027	Observational	Not applicable	Unclear		ic) // 089 ic) // 003 20
29 131027 30 131027	Observational	Not applicable	Case report	Mechanism	/ Aged /, Cli
31 131027 32 131028	iviodening // Observatio	Not applicable		Epidemiology // Transmission	/ Com Ad ic) // Co
33 131028 34 131028 35 131028	Diservational	Not applicable	Case series/Case contro	Epidemiology	254-64 Co / Amino 20
36 131028 37 131028	port, Non-U.S. Gov't				iment // / Age Ad
38 131028	Modelling	Not applicable		Transmission	Co
Ready	port Non-US Gov't				0%

$(\epsilon) \rightarrow c $	COVID-19 Evidence Alerts.ris	🚳 💿 🔤 🕓 🛱 ≡
6 Getting Started 🏠 Most Visited 🦳 AN	– JOUR – 32014114	ate 💮 Best Questions to A 🚿
	– NOTALATEGORYWEAPPRAISE	
C2 C3	– – Modelling study: epidemics dynamic	
ER	-	
	– JOUR – 32150748	
C1	- DoesNotMeetOurCriteria	
C2 C3	 Prognosis Searched for news and public health reports of confirmed COVID-19 cases 	
ER		
	– JOUR – 32151335	
	- DoesNotMeetOurCriteria	
C2	- Prognosis	
C3 ER	- 9 hospitalized pregnant women in their third trimester admitted to a single site in China -	
TY	– JOUR	
	- 32171076 - DoesNotMeetOurCriteria	
	- Prognosis	
С3	– 191 hospitalized patients admitted at 2 sites in China	
EK TY	– – JOUR	
AN	- 32187464	
C1 (2)	- HigherQuality - Treatment	
С3	_	
	– JOUR – 32192580	
C1	- NotACategoryWeAppraise	
C2 C3	- Prognosis - Epidemiology of transmission	
ER	_	
	- JOUR	
AN C1	- 32202261 - NotACategoryWeAppraise	
C2		
C3 FR	- <u>Epidemologic</u> modelling	
TY	– JOUR	
	- 32205204 - DoesNotMeetOurCriteria	
	- Treatment	
С3	 Not a randomized controlled trial 	
ER		
TY	– JOUR	
AN C1	- 32205269 - NotACategoryWeAppraise	
C2	-	
С3	- Descriptive study	
ER TY	– JOUR	

← → C' @	https://www.epistemonikos.org/documents/check_documents	⊌ ☆	⊻ III\ 🗉 🏟	🗈 🔤 🔇	# Ξ
🍯 Getting Started 🛛 🌣 Most Visit	ed 📄 Personale 📄 HIRU 📄 Open access 📄 McMaster 📄 Google tools 📄 Clinical 🔀 Citrix XenApp - Log 🖨 Mene 🖨 My Acc	unt 🔾 McMaster Universit	U Coronavirus Update	Best Questions to A	>>
📅 Epistemonikos	About - Help - Contact			Sign up Login	• •
	Check documents				
	References ids (1 per line. max: 100)				

32156607 32182724 32190785 32183930 32191691					
32182724					
32156607					
15302738					
32079150					
32056407					
32174053					
32183920					
	32174053 32056407 32079150	32174053 32056407 32079150	32174053 32056407 32079150	32174053 32056407 32079150	32174053 32056407 32079150

 -			
	DJAN	ASE	

About us How to use

Our methods

Updated report

Key Concepts Multilinguality Epistemonikos API

THE FOUNDATION

Epistemonikos Foundation Contact + Feedback Follow us

LEGAL

Terms and Conditions

Privacy policy

Epistemonikos is licensed under Licence Creative Commons Attribution 3.0 Unported Commons

TEpistemonikos About - Help - Contact

Check documents

References ids (1 per line. max: 100)	Not_found
32183920	U Unrecognized
32174053	
32056407	2
32079150	
15302738	
32156607	
32182724	
32190785	
32183930	
32191691	11.
	1110

Get Documents

Total: 57 references 🕑 Export all

57 articles (57 References) Revert

Primary study

First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan.

- Authors » Cheng SC , Chang YC , Fan Chiang YL , Chien YC , Cheng M , Yang CH , Huang CH , Hsu YN
- Journal » Journal of the Formosan Medical Association = Taiwan yi zhi
- Year » 2020
- Links » Pubmed , DOI , PubMed Central
- This article is included in 6 Systematic reviews

Abstract About this article Related evidence


An outbreak of respiratory illness proved to be infected by a 2019 novel coronavirus, officially named Coronavirus Disease 2019 (COVID-19), was notified first in Wuhan, China, and has spread rapidly in China and to other parts of the world. Herein, we reported the first confirmed case of novel coronavirus pneumonia (NCP) imported from China in Taiwan. This case report revealed a natural course of NCP with self-recovery, which may be a good example in comparison with medical treatments.


I Inclose if ind

	references_2020-07-10T21 44 22.893Z.ris	B 🕅 🕻		
	Q~ Find			
	TY – JOUR	Best Ques	tions to A	77
Epistemonikos	LA – English TI – Passengers' destinations from China: low risk of Novel Coronavirus (2019-nCoV) transmission into Africa and South America.	Sign up	Login	 • •
	AU – Haider N AU – <u>Yavlinsky</u> A			
	AU – Simons D			
	AU – Osman AY AU – Ntoumi F	***		
	AU – Zumla A			
	AU - Kock R AB - Novel Coronavirus (2019-nCoV [SARS-COV-2]) was detected in humans during the last week of December 2019 at Wuhan city in China, and caused			
	24 554 cases in 27 countries and territories as of 5 February 2020. The objective of this study was to estimate the risk of transmission of 2019-			
	nCoV through human passenger air flight from four major cities of China (Wuhan, Beijing, Shanghai and Guangzhou) to the passengers' destination countries. We extracted the weekly simulated passengers' end destination data for the period of 1–31 January 2020 from FLIRT, an online air			
	travel dataset that uses information from 800 airlines to show the direct flight and passengers' end destination. We estimated a risk index of 2019-nCoV transmission based on the number of travellers to destination countries, weighted by the number of confirmed cases of the departed city			
	reported by the World Health Organization (WHO). We ranked each country based on the risk index in four quantiles (4th quantile being the highest			
	risk and 1st quantile being the lowest risk). During the period, 388 287 passengers were destined for 1297 airports in 168 countries or territories across the world. The risk index of 2019-nCoV among the countries had a very high correlation with the WHO-reported confirmed cases			
	(0.97). According to our risk score classification, of the countries that reported at least one Coronavirus-infected pneumonia (COVID-19) case as			
	of 5 February 2020, 24 countries were in the 4th quantile of the risk index, two in the 3rd quantile, one in the 2nd quantile and none in the 1st quantile. Outside China, countries with a higher risk of 2019-nCoV transmission are Thailand, Cambodia, Malaysia, Canada and the USA, all of			
	which reported at least one case. In pan-Europe, UK, France, Russia, Germany and Italy; in North America, USA and Canada; in Oceania, Australia			
	had high risk, all of them reported at least one case. In Africa and South America, the risk of transmission is very low with Ethiopia, South Africa, Egypt, Mauritius and Brazil showing a similar risk of transmission compared to the risk of any of the countries where at least one case			
	is detected. The risk of transmission on 31 January 2020 was very high in neighbouring Asian countries, followed by Europe (UK, France, Russia			
	and Germany), Oceania (Australia) and North America (USA and Canada). Increased public health response including early case recognition, isolation of identified case, contract tracing and targeted airport screening, public awareness and vigilance of health workers will help			
	mitigate the force of further spread to naïve countries. T2 - Epidemiology and infection			
	VL – 148			
	SP - e41 SN - 1469-4409	-		
	PY - 2020			
	DA - 2020 D0 - 10.1017/S0950268820000424			
	U1 – 32100667[pmid] DB – EPISTEMONIKOS			
	<pre>UR - http://www.epistemonikos.org/documents/4defd6d1768250771432fe7752ca7c1a73977e17</pre>			
	ER –			
	TY – JOUR			
	LA - English TI - <u>Epidemiologic</u> characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea.			
	AU – Ki M AU – Task Force for 2019–nCoV			
	AB – In about 20 days since the diagnosis of the first case of the 2019 novel coronavirus (2019–nCoV) in Korea on January 20, 2020, 28 cases			
	have been confirmed. Fifteen patients (53.6%) of them were male and median age of was 42 years (range, 20–73). Of the confirmed cases, 16, 9, and 3 were index (57.2%), first-generation (32.1%), and second-generation (10.7%) cases, respectively. All first-generation and second-generation			
	patients were family members or intimate acquaintances of the index cases with close contacts. Fifteen among 16 index patients had entered Korea			
	from January 19 to 24, 2020 while 1 patient had entered Korea on January 31, 2020. The average incubation period was 3.9 days (median, 3.0), and the reproduction number was estimated as 0.48. Three of the confirmed patients were asymptomatic when they were diagnosed. Epidemiological			
	indicators will be revised with the availability of additional data in the future. Sharing epidemiological information among researchers			
	worldwide is essential for efficient preparation and response in tackling this new infectious disease. T2 – Epidemiology and health			

T2 - Epidemiology and health

	Zotero					
		verything		⇒ ▼		0 C
My Library	Creator	^ ∥ ᡛ	Info	Notes Ta	ags Related	
CochraneCovidExport	-	_				_
COVID-19 Evidence Alerts	Aarogyam UK			outbreak and loo	ckdown. Yoga ha	s potential
Epistemonikos	Aarogyam UK			benefit for pain management; so	o developed a Te	le-Yoga
My Publications	Aarogyam UK			therapy program	n and evaluated i	
Duplicate Items	Abbasi S			single arm study		
	Abdalhamid B			ClinicalTrials.gov	V	
Unfiled Items	Abdalhamid B		Volume			
🕤 Trash	Abdel Jalil MH		lssue			
	Abdulmajeed K		Pages			
	Abhari RS			2020		У
	Abril-Perez C		Series			
	Acar AC		Series Title			
	Acibadem University		Series Text			
	Acibadem University		Journal Abbr			
	Acuna-Zegarra MA		Language			
	Acuna-Zegarra MA		DOI			
	Adair LB 2nd		ISSN			
	Adelino R		Short Title			
	Adiga A			https://clinicaltr	ials.gov/show/N	CT0445
0	Affiliated Hospital of Southwest Medical University		Accessed		10 0	
*Adaptation, Psychological // Adult //	Affiliated Hospital of Zunyi Medical University			Cochrane COVID	–19 Register	
*Air Travel // *Betacoronavirus // Chi	aggarwal N		Loc. in Archive	14079938		
	Aguiar D		Library Catalog Call Number			
*Ambulatory Care Facilities // *Betacor	Agyapong VIO					
*Anxiety // Betacoronavirus /*isolatio	Ahammed K		Rights Extra			
	Ahmadi M			2020-07-10, 6:	12·22 n m	
Q	Ahmed MAM					
· · · · · · · · · · · · · · · · · · ·	AL 1.4.7		Modified	2020-07-10, 6:	15.25 p.m.	





		- S References.ris	
	U1 ER	- 32541210[pmid]	
	LR		
		- JOUR	
		- Accelerated launch of video visits in ambulatory neurology during COVID-19: Key lessons from the Stanford experience.	
		– 2020 – Yang L	
		– Brown–Johnson CG	
Co		- Miller-Kuhlmann R - Kling SMR	
CU	AU	- Kling SMR	ubscribe
100		- Saliba-Gustafsson EA - Shaw JG	abscribe
•	Δ11		
Sool	rch in ^{AU}	- Winger M - The COVID-19 pandemic has rapidly moved telemedicine from discretionary to necessary. Here we describe how the Stanford Neurology Department: 1) rapidly adapted	
Seal		The covers is pundemic has rupidly moved celementer in marginal for necessary increase a covers is pundemic has rupidly adapted	
		the COVID-19 pandemic, resulting in over 1000 video visits within four weeks and 2) accelerated an existing quality improvement plan of a tiered roll out of video	
	V1S	its for ambulatory neurology to a full-scale roll out. Key issues we encountered and addressed were related to: equipment/software, provider engagement, workflow/ age, and training. Upon reflection, the key drivers of our success were provider engagement and a supportive physician champion. The physician champion played a	rticlos
Prev	ention cri	tical role understanding stakeholder needs, including staff and physicians' needs, and creating workflows to coordinate both stakeholder groups. Prior to COVID-10	articles
	phy	sician interest in telemedicine was mixed. However, in response to county and state stay-at-home orders related to COVID-19, physician engagement changed "	ssessment
Pre	evention com	prefery, are providers wanted to convert a majority of visits to video visits as quickly as possible. Rapid deproyment of neurology video visits across are its	ed articles
Dia	sub	specialties is feasible. Our experience and lessons learned can facilitate broader utilization, acceptance, and normalization of video visits for neurology patients the present as well as the much anticipated post-pandemic era.	
		- http://www.epistemonikos.org/documents/08715a1bacffee8d4b3eae2d012fba42380de39e	
	т2	- Neurology	
Ep		- 1526-632X	
Pro		- 10.1212/WNL.00000000010015	
	U1 ER	- 32611634[pmid]	
	LN	-	
Qua	rantine TY		5
		- Associations of stay-at-home order and face-masking recommendation with trends in daily new cases and deaths of laboratory-confirmed COVID-19 in the United	
	Sta PY	- 2020	
S		- Jie Xu	
	AU	- Sabiha Hussain	
	Pharn AU	- Guanzhu Lu	
	▶ Physic AU	- Shi Wei - Wei Bao	
	Comp Au	- Lanjing Zhang	
	▶ Proce AB	- OBJECTIVE: To examine the associations of stay-at-home order and face-masking recommendation with trends in daily new cases and deaths of laboratory-confirmed	
	Diot 2	onavirus disease 2019 (COVID-19) in the United States DESIGN: Piecewise log-linear modelling of temporal trends with turning-points, followed by quasi-experimental	
	· Dieta stu	dy on trend turning-point. Simulation studies were carried out to understand the outcomes under the scenarios if early-implementation and removal of stay-at-home	
	0117	er occurred. SETTING: Population data in the United States PARTICIPANTS: Residents in the U.S., who were affected by the stay-at-home and face-masking policies MAIN – COME MEASURES: Turning-points of the daily new cases and deaths of COVID-19, and COVID-19 time-varying reproduction numbers (Rt) in the U.S. RESULTS: The number and	
	▼ ^{Publi} the	proportion of U.S. residents under SAHO increased between March 19 and April 7, and plateaued at 29,0829,980 and 88.6%, respectively. The trend in COVID-19 daily	
		es reduced after March 73 (PZM MMT) and further reduced on Anril 3 (PZM MMT) which was associated with implementation of SAHD by 10 states on March 73 and the	
	▼ Sc Cen	ters for Disease Control and Preventions recommendation of face-masking, respectively. Similar turning points were identified in the trends of daily deaths with a	DS
	Lag	time. The estimates of Rt based on the 3 reported mean serial-intervals of COVID-19 all started to decline on March 19, when SAHO was first implemented in the U.S. declined faster after March 23. After a short plateau, Rt continued to decline after April 3 and fell below/around 1.0 on April 13. CONCLUSIONS: There were 2	
		ning points of COVID-19 daily new cases or deaths in the U.S., which appeared to associate with implementation of SAHO and the CDC face-masking recommendation.	
		ulation on early-implementation and removal of SAHO reveals considerable impact on COVID-19 daily new cases and deaths. These findings may inform decision-making of	
		ting SAHO and face.	
(-	- http://www.epistemonikos.org/documents/09a544128bf0f39bbaf3a35c0dc4c98f48c83fd2	
		- medRxiv - 10.1101/2020.05.01.20088237	
		- 32637967[pmid]	

••• • Z z	otero Downloads	×	Cochrane	e COVID-19 Stud 🗙 🎆 COVID-19 Evidence	e Alert: 🗙 🛛 🐔 Epistemonikos: Database 🗙	Quarantine for COVID-19 X	DVID-19 X 👩 Index - FHIR v4.0.1 X 🕇		
← → ♂ ⓓ		🔽 🔒 h	nttps://covid	l-19.cochrane.org/?pn=1		··· 🗵 🏠	👱 III\ 🗉 🏟 💿 🚾 😋 🤃 👬 🗏		
🥌 Getting Started 🔅	Most Visited 🗎	Personale	🗎 HIRU 📋] Open access 🗎 McMaster 🗎 Google too	ls 📄 Clinical 🌐 Citrix XenApp - Log 💮 N	lene My Account 💮 🥥 McMaster Universit [U Coronavirus Update 🔀 Best Questions to A >>		
COV	hrane (ID-19 Register		evidence. d decisions. ealth.		4 32118644 15158632 32113824 search	About Help 3644 15158632 32113824 32131908 32144116 32017661 31992387 23041021 32124990 32164400 12690091			
UPDATED		^	Select All	Order by Newest First 🗸 Results	per page 15 V	Showing 1 - 15 of 12,26	2 studies Prev 1 2 3 4 5 6 7 Next		
Last Day		124		(
Last 3 Days		575		GUALANO 2020A					
Last Week		941	Effects of Covid-19 Lockdown on Mental Health and Sleep Disturbances in Italy						
Last Month		4218		ां Study Type	i) Study Aim	(i) Study Design	(i) Intervention Assignment		
Last 3 Months		11017		Observational	Other	Case Series/Case Control/Cohort	Not Applicable		
From And To				References (1)					
STUDY REFERENCE T	YPE	~		(
STUDY CHARACTERISTICS ~			MØLLER-SØRENSEN 2020	schemical Ventilation and FCMO					
PICO data not currently available for all studies		tudies		COVID-19 Assessment with Bedside Lung Ultrasound in a Population of Intensive Care Patients Treated with Mechanical Ventilation and ECMO					
POPULATION		~		 Study Type Observational 	(i) Study Aim Diagnostic/Prognostic	 Study Design Case Series/Case Control/Cohort 	Intervention Assignment Not Applicable		
INTERVENTION		~		References (1)	Treatment And Management				
OUTCOME		~							
			ZHAO 2020BA Prediction of the Number of Patients Infected with COVID-19 Based on Rolling Grey Verhulst Models						
				ां Study Type	(i) Study Aim	① Study Design	① Intervention Assignment		
				Modelling	Transmission	Other	Not Applicable		
					Epidemiology		1939 Selected <u>Export</u> <u>Clear</u>		
				References (1)					

← → ♂ ⓓ		🖸 🔒 https://covid-19.cochrane.org/?q=k(32174069 32083328 32102279 23891402 32046819 32064855 90%) 🚥 🖂 🏠 🖳 🖉 🕼 🗈 🤷 😋 🌾								
🧕 Getting Started 🛛 🌣 Most Vis	sited 🚞	Personale 📋 HIRU 📋 Open access 📋 McN	Aaster 📄 Google tools 📄 Clinical 🌐 Citrix XenApp -	- Log 🖨 Mene 🕀 My Account 🕀 🥥 McMas	ster Universit 🕕 Coronavirus Update 🜐 Best Questions to A 🚿					
Cochran COVID-19 Study Register	Ir	rusted evidence. nformed decisions. etter health.	Search		About Help					
UPDATED^Last Day0Last 3 Days0Last Week0Last Month0Last 3 Months0		by T4069 32083328 32102279 23891402 32046819 32064855 32127123 32187464 15560695 32151335 32164089 32026671 32114744 32118644 15158632 32113824 32131908 32144116 32017661 31992387 23041021 32124990 32164400 12690091 × II Order by Relevance v Results per page 15 v V 1 2 Next DANIELSSON 2012 Novel coronavirus associated with severe respiratory disease: case definition and public health measures								
From And To STUDY REFERENCE TYPE		 Study Type Observational 	ी Study Aim Mechanism	i Study Design Case Report	 Intervention Assignment Not Applicable 					
STUDY CHARACTERISTICS \vee		References (1)								
PICO data not currently available for all studies		CHICTR2000029308								
POPULATION ~		A randomized, controlled open-label trial to evaluate the efficacy and safety of lopinavir-ritonavir in hospitalized patients with novel coronavirus pneumonia (COVID-19)								
INTERVENTION ~		Study Type Interventional	 Study Aim Treatment And Management 	Study Design Parallel/Crossover	 Intervention Assignment Randomised 					
OUTCOME ~		n Population (7)	Intervention (1)	© Comparison (1)	Outcome (2)					
		Male And Female COVID-19 Adult Aged (65+) References (2)	Lopinavir And Ritonavir	Usual Care	Time To Clinical Improvement Clinical Improvement					
		- 2020A Report on the Epidemiological Feat	ures of Coronavirus Disease 2019 (COVID-19) Ou	tbreak in the Republic of Korea from Janua	ry 19 to March 2, 2020					

What does this address and what it does not address

- It is a proof of concept for and approach to:
 - Obtaining meta-data for records from existing repositories
- It does not address:
 - Comprehensive searching (retrieving all references from all databases)
 - Federated searching (searching multiple databases at the same time)
 - De-duplication, or finding references unique to each repository
- It is a starting, not final point

Another use case

- Identifying the most current and comprehensive living review on social distancing
 - If repositories of living review on social distancing were allowing extraction of meta-data (eg # of trials included, search end date) ina RIS-like format (e.g. COKA FHIR)
 - If one had a tool to combine/compare the RIS
- The task would be solved

Why Improve my RIS is important?

• Because the problem in achieving most of our goals is not technical (how to handle the data), but political (willingness to share data).

 Choosing a simple solution offers a cheap way of proofing the concept that data can be AND ARE shared

• Improve my RIS would provide pilot data for fundraising

Is it OK if I upload to google docs and edit there? I would paste screenshots following the following script

1 - Paste in Epipstemonikos 'improve my RIS' a list of PMID from your example (this is the preliminary URL [limited to 100 IDs by now]: <u>https://www.epistemonikos.org/documents/check_documents</u>)

2 - Return the % of articles from that list that are in our database

3- Export a RIS with the following metadata in M3 field (the same you are using): Primary study/ RCT or non- RCT / reports data or does not report data.

Then,

Starting from the question of the example review in

L·OVE: <u>https://app.iloveevidence.com/loves/5e6fdb9669c00e4ac072701d?question_domain=5b1dcd8ae611de7</u> ae84e8f14&population=5e7fce7e3d05156b5f5e032a&intervention=5e93a6fc3552583c288cc9c7

1- Export a RIS

- 2- (I would not explain again how to go get from RIS to list of PMIDs)
- 3- Paste list of IDs in Cochrane Register
- -- End of demo --

Any suggestion is more than welcome Gabriel